Alexandria Real Estate Equities Inc  

(Public, NYSE:ARE)   Watch this stock  
Find more results for ARE
68.09
+0.66 (0.98%)
Jun 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 67.14 - 68.25
52 week 64.09 - 78.43
Open 67.33
Vol / Avg. 460,158.00/895,209.00
Mkt cap 5.38B
P/E 62.34
Div/yield 0.65/3.82
EPS 1.09
Shares 79.02M
Beta 1.31
Inst. own 81%
Sep 11, 2013
Alexandria Real Estate Equities Inc at Bank of America Merrill Lynch Global Real Estate Conference Add to calendar
Jul 29, 2013
Q2 2013 Alexandria Real Estate Equities Inc Earnings Release Add to calendar
May 20, 2013
Alexandria Real Estate Equities Inc Annual Shareholder Meeting
May 13, 2013
Alexandria Real Estate Equities Inc at JMP Securities' Research Conference
Apr 30, 2013
Alexandria Real Estate Equities Incorporated First Quarter 2013 Results - Webcast
Apr 29, 2013
Q1 2013 Alexandria Real Estate Equities Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 19.57% 17.63%
Operating margin 19.57% 17.63%
EBITD margin - 61.75%
Return on average assets 1.66% 1.51%
Return on average equity 2.84% 2.16%
Employees 217 -
Carbon Disclosure Rating - -

Address

Suite 299, 385 East Colorado Boulevard
PASADENA, CA 91101
United States - Map
+1-626-5780777 (Phone)
+1-626-5780770 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT). The Company is an owner and REIT, and life science real estate company, focused on science-driven cluster development through the ownership, operation, management, selective acquisition, development, and redevelopment of properties containing life science laboratory space. The Company is a provider of real estate, technical infrastructure, and services to the life science industry. Client tenants include institutional (universities and independent non-profit institutions), pharmaceutical, biotechnology, medical device, product, and service entities and government agencies, , medical device companies, industrial biotech companies, venture capital firms, and life science product and service companies. As of December 31, 2012, the Company�s operating properties were approximately 93.4% leased.

Officers and directors

Joel S Marcus Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Dean A Shigenaga Chief Financial Officer, Senior Vice President, Treasurer
Age: 45
Bio & Compensation  - Reuters
Stephen A. Richardson Chief Operating Officer, Regional Market Director - San Francisco
Age: 51
Bio & Compensation  - Reuters
Peter M. Moglia Chief Investment Officer
Age: 45
Bio & Compensation  - Reuters
Richard B. Jennings Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
James H. Richardson Director
Age: 52
Bio & Compensation  - Reuters
John L. Atkins III Independent Director
Age: 68
Bio & Compensation  - Reuters
Maria C. Freire Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Richard H. Klein Independent Director
Age: 56
Bio & Compensation  - Reuters